These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33371333)

  • 1. Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy.
    Jeong HY; Kim H; Lee M; Hong J; Lee JH; Kim J; Choi MJ; Park YS; Kim SC
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
    Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
    Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.
    Yamashita-Kashima Y; Yoshimura Y; Fujimura T; Shu S; Yanagisawa M; Yorozu K; Furugaki K; Higuchi R; Shoda J; Harada N
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):659-671. PubMed ID: 30659304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of HER2 expression with an 18F-fluoride labeled aptamer.
    Kim HJ; Park JY; Lee TS; Song IH; Cho YL; Chae JR; Kang H; Lim JH; Lee JH; Kang WJ
    PLoS One; 2019; 14(1):e0211047. PubMed ID: 30682091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer-conjugated and doxorubicin-loaded grapefruit-derived nanovectors for targeted therapy against HER2
    Tang Z; Jun Y; Lv Y; Li Y; Zhang Z; Tao M; Chen X; He J; Zhang L; Wang QL
    J Drug Target; 2020 Feb; 28(2):186-194. PubMed ID: 31134823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine.
    Le Joncour V; Martins A; Puhka M; Isola J; Salmikangas M; Laakkonen P; Joensuu H; Barok M
    Mol Cancer Ther; 2019 Oct; 18(10):1721-1730. PubMed ID: 31292166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of growth of HER2-positive ovarian cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate in mouse xenograft model.
    Yu L; Wang Y; Yao Y; Li W; Lai Q; Li J; Zhou Y; Kang T; Xie Y; Wu Y; Chen X; Yi C; Gou L; Yang J
    Int J Gynecol Cancer; 2014 Sep; 24(7):1158-64. PubMed ID: 24987913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
    Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aptamer Enables Consistent Maytansine Delivery through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy.
    Tan Y; Peng Y; Ai L; Li Y; Qu YX; Wang D; Su Y; Deng T; Fu T; Zhao Z; Wang XQ; Tan W
    Bioconjug Chem; 2020 Jul; 31(7):1766-1774. PubMed ID: 32463664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro.
    Liu Z; Duan JH; Song YM; Ma J; Wang FD; Lu X; Yang XD
    J Transl Med; 2012 Jul; 10():148. PubMed ID: 22817844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of DNA aptamers for extra cellular domain of human epidermal growth factor receptor 2 to detect HER2 positive carcinomas.
    Sett A; Borthakur BB; Bora U
    Clin Transl Oncol; 2017 Aug; 19(8):976-988. PubMed ID: 28224267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.
    Inoue S; Ding H; Portilla-Arias J; Hu J; Konda B; Fujita M; Espinoza A; Suhane S; Riley M; Gates M; Patil R; Penichet ML; Ljubimov AV; Black KL; Holler E; Ljubimova JY
    Cancer Res; 2011 Feb; 71(4):1454-64. PubMed ID: 21303974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer.
    Su F; Zhu S; Ruan J; Muftuoglu Y; Zhang L; Yuan Q
    Oncotarget; 2016 Jan; 7(4):4142-54. PubMed ID: 26716652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Intelligent DNA Nanorobot with
    Ma W; Zhan Y; Zhang Y; Shao X; Xie X; Mao C; Cui W; Li Q; Shi J; Li J; Fan C; Lin Y
    Nano Lett; 2019 Jul; 19(7):4505-4517. PubMed ID: 31185573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody).
    Kim HJ; Sung HJ; Lee YM; Choi SI; Kim YH; Heo K; Kim IH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32384770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
    Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
    Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.